Below are the most recent publications written about "Acute Coronary Syndrome" by people in Profiles.
-
Senguttuvan NB, Suman F, Paneerselvam T, Malepati B, Ramesh S, Vallivedu MV, Badimela P, Ramadoss M, Iyer M, Krishnamurthy P, Vinod Kumar B, Balasubramaniyan JV, Sadhanandham S, Jebaraj R, Manokar P, Muralidharan TR, Murthy JS, Thanikachalam S, Krishnamoorthy P, Baber U, Karthikeyan G. Comparison of the effect of Morphine and Fentanyl in patients with acute coronary syndrome receiving Ticagrelor - The COMET (Comparison Morphine, Fentayl and Ticagrelor) randomized controlled trial. Int J Cardiol. 2021 05 01; 330:1-6.
-
Baber U, Mehran R. Extending the aspirin-free paradigm to patients with acute coronary syndrome: is it time to change guidelines? EuroIntervention. 2020 Oct 23; 16(8):620-622.
-
Baber U, Dangas G, Angiolillo DJ, Cohen DJ, Sharma SK, Nicolas J, Briguori C, Cha JY, Collier T, Dudek D, Džavik V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta S, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM, Mehran R. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020 10 01; 41(37):3533-3545.
-
Chandrasekhar J, Baber U, Sartori S, Aquino M, Moalem K, Kini AS, Rao SV, Weintraub W, Henry TD, Vogel B, Ge Z, Muhlestein JB, Weiss S, Strauss C, Toma C, DeFranco A, Claessen BE, Keller S, Baker BA, Effron MB, Pocock S, Dangas G, Kapadia S, Mehran R. Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. Clin Res Cardiol. 2020 Jun; 109(6):725-734.
-
Ge Z, Baber U, Claessen BE, Chandrasekhar J, Chandiramani R, Li SX, Sartori S, Kini AS, Rao SV, Weiss S, Henry TD, Kapadia S, Muhlestein B, Strauss C, Toma C, DeFranco A, Effron MB, Keller S, Baker BA, Pocock S, Dangas G, Mehran R. Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. J Thromb Thrombolysis. 2019 Jul; 48(1):42-51.
-
Chandiramani R, Chen H, Aoi S, Giustino G, Claessen B, Sartori S, Aquino M, Sorrentino S, Cao D, Goel R, Kini A, Rao S, Weintraub W, Henry TD, Kapadia S, DeFranco A, Muhlestein JB, Toma C, Effron MB, Keller S, Baker BA, Pocock S, Baber U, Mehran R. Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2020 04 01; 95(5):885-892.
-
Fox AN, Skrepnek GH, Miller JL, Schwier NC, Ripley TL. Optimal Medical Therapy Prescribing Patterns and Disparities Identified in Patients with Acute Coronary Syndromes at an Academic Medical Center in an Area with High Coronary Heart Disease-Related Mortality. Am J Cardiovasc Drugs. 2019 Apr; 19(2):185-193.
-
Faggioni M, Baber U, Chandrasekhar J, Sartori S, Weintraub W, Rao SV, Vogel B, Claessen B, Kini A, Effron M, Ge Z, Keller S, Strauss C, Snyder C, Toma C, Weiss S, Aquino M, Baker B, Defranco A, Bansilal S, Muhlestein B, Kapadia S, Pocock S, Poddar KL, Henry TD, Mehran R. Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. Catheter Cardiovasc Interv. 2019 Jul 01; 94(1):53-60.
-
Baber U, Leisman DE, Cohen DJ, Gibson CM, Henry TD, Dangas G, Moliterno D, Kini A, Krucoff M, Colombo A, Chieffo A, Sartori S, Witzenbichler B, Steg PG, Pocock SJ, Mehran R. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004945.
-
Schoos M, Power D, Baber U, Sartori S, Claessen B, Camaj A, Steg P, Ariti C, Weisz G, Witzenbichler B, Henry T, Cohen D, Antoniucci D, Krucoff M, Hermiller J, Gibson C, Chieffo A, Moliterno D, Colombo A, Pocock S, Dangas G, Mehran R. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. Am J Cardiol. 2019 03 01; 123(5):709-716.